Once again, DOC off in 20 different directions and no marketable product or revenues for ONCS. You have to set priorities. DOC spent $200m in capital at ADXS and delivered no products. This deal will take years and years before any revenue. Until then just cash drain. Terrible strategy for a company with only 9 months cash left until the next dilution, and doing R/S to get its stock price out of the gutter. Once again DOC taking another company down the road to ruin. Some people [noram] never learn.